论文部分内容阅读
本文对１７ 例垂体性侏儒症病儿进行了国产基因重组人生长激素（γｈＧＨ） 疗效观察，治疗前平均年身高增长１－９５±１ ．０６ｃｍ／ａ（ 厘米／年），治疗６ 个月平均年身高增长１１－４３ ±１ ．６２ｃｍ／ａ，经ｔ 检验，ｔ＝ ７－０２ Ｐ＜０ ．０１，说明了国产的γｈＧＨ也有良好的促生长作用，而且治疗前后骨龄增长不明显，治疗前骨龄为４．７７ ±３ ．４ 岁，治疗６ 个月骨龄为５－３ ±３－３（ｔ＝ ０－０８１ ，Ｐ＞ ０ ．０５），全部病儿治疗后食量，体力，睡眠改善，除１ 例出现注射部位疼痛，１ 例出现周身水肿外，无异常临床症状，实验室检查仅ＡＬＰ较用药前有所提高，用药前ＡＬＰ 值为１１８９．８８ ±９－４３ ，用药后１ 个月ＡＬＰ值为１５０－５８ ±１９－７９，虽然与用药前比较有所提高，但是经检验（ｔ＝ １－８０ ，Ｐ＞０－０５） 无显著性差异，经补充ＶｉｔＤ 和钙剂ＡＬＰ恢复正常。结果表明国产γｈＧＨ 具有疗效确实，无副作用的优点。
In this paper, 17 cases of pituitary dwarfism children were treated with recombinant human growth hormone (γhGH) efficacy observed before treatment, the average annual height growth of 1-95 ± 1. 06cm / a (cm / year), 6 months average annual height growth of 11-43 ± 1. 62cm / a, t test, t = 7-02 P <0. 01, indicating that domestic γhGH also has a good role in promoting growth, and bone growth before and after treatment was not obvious, before treatment, the bone age was 4.77 ± 3. 4 years old, the bone age was 5-3 ± 3-3 (t = 0-081, P> 0.05) after 6 months of treatment. The food intake, physical strength and sleep improvement of all the sick children were improved after treatment. Except in 1 case, 1 cases of peripheral edema, no abnormal clinical symptoms, laboratory tests only increased ALP before treatment, ALP value before treatment was 1189.88 ± 9-43, 1 month after treatment ALP value of 150-58 ± 19 -79, although compared with before treatment increased, but the test (t = 1-80, P> 0-05) no significant difference, after supplementation VitD and calcium ALP returned to normal. The results show that domestic γhGH has the effect of a real, no side effects.